ArticleWorld journal of urology2025
Pharmacotherapy for BPH-related LUTS: associations between medication patterns, persistence, and treatment failure.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate real-world medical treatment profiles and the impact of prescription patterns on treatment persistence and failure in men with benign prostatic hyperplasia through a retrospective chart review.
methodsWe reviewed the medical charts of 779 patients who initiated pharmacotherapy with α-blockers (ABs), 5α-reductase inhibitors (5ARIs), or phosphodiesterase-5 inhibitors (PDE5Is) between January 2014 and December 2021. Baseline characteristics, prescription patterns, and the addition of antimuscarinics or β3-agonists were assessed via multivariable Cox proportional hazards models for the impact of these variables on treatment persistence, development of acute urinary retention (AUR), and progression to surgery. Missing baseline values were addressed via multiple imputation.
resultsThe median treatment duration was 29 months. Most patients (76%) initiated AB monotherapy, followed by AB plus 5ARI (6.5%) and AB plus antimuscarinics (5.5%). Forty-one men developed AUR, and 68 required surgery. 5ARI use and PDE5I use were associated with greater, whereas initial presentation with AUR (iAUR) was associated with lower treatment persistence. 5ARI use reduced AUR risk, whereas prostate enlargement increased the likelihood of AUR. Progression to surgery was associated with larger prostate volume, postvoid residual volume > 100 mL, and iAUR.
conclusionsDespite their limited use, 5ARIs, PDE5Is, antimuscarinics, and β3-agonists were associated with longer treatment persistence. Additionally, 5ARIs were associated with a significant reduction in AUR risk.
Indexed as
Identifiers
40266351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.